Eisai ditches extended release rabeprazole
This article was originally published in Scrip
Eisai has dropped from development an extended release capsule formulation of its proton pump inhibitor Aciphex (rabeprazole) following a complete response letter from the US FDA in February.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.